Obstetric and Gynecologic Imaging

Why Is Imaging Not Recommended for Early-Stage Vulvar Cancer Staging?

·
Why Is Imaging Not Recommended for Early-Stage Vulvar Cancer Staging?

A 68-year-old patient is in your clinic for consultation. A recent biopsy of a small vulvar lesion confirmed squamous cell carcinoma. The pathology report is clear: the tumor measures 1.6 cm at its greatest dimension and has a stromal invasion of only 0.8 mm. It appears confined to the vulva, and her groin exam is unremarkable. As you plan for definitive surgical treatment, the question of staging arises. Do you order a CT, MRI, or PET/CT to look for metastatic disease before heading to the operating room? For this specific clinical scenario—a small, superficially invasive vulvar cancer—the American College of Radiology (ACR) Appropriateness Criteria advises that routine imaging is Usually not appropriate. This article details the evidence-based rationale for avoiding imaging in this low-risk population and outlines the correct clinical workflow.

Who Fits This Early-Stage Vulvar Cancer Scenario?

This guidance applies to a very specific subset of patients with newly diagnosed vulvar cancer prior to any treatment. The inclusion criteria are precise and based on the 2021 FIGO (International Federation of Gynecology and Obstetrics) staging system, corresponding to Stage IA disease.

Inclusion Criteria for this Workflow:

  • Tumor Size: The primary tumor is less than or equal to 2 cm in its largest dimension.
  • Tumor Location: The cancer is confined to the vulva or perineum.
  • Depth of Invasion: There is less than or equal to 1 mm of stromal invasion as measured from the epithelial-stromal junction of the most superficial adjacent dermal papilla to the deepest point of invasion.
  • Nodal Status: The inguinal-femoral lymph nodes are not clinically suspicious on physical examination.

It is crucial to distinguish this low-risk group from patients with slightly more advanced disease, as their management differs significantly. This guidance does not apply if the patient presents with:

  • Deeper Invasion: Stromal invasion greater than 1 mm, even with a small primary tumor.
  • Larger Tumors: A primary tumor greater than 2 cm.
  • Clinically Suspicious Nodes: Any palpable, firm, or fixed lymph nodes in the groin, regardless of the primary tumor characteristics.

Patients with any of these features fall into a different risk category and typically require imaging to evaluate for nodal and distant metastatic disease.

What Are the Clinical Questions During Staging for This Scenario?

For a patient with a confirmed diagnosis of early-stage vulvar cancer, the primary goal of staging is to determine the extent of the disease, which directly informs the treatment plan. The key question is whether the cancer has spread beyond the primary site.

Inguinal Lymph Node Metastasis: This is the most critical question in vulvar cancer staging. The inguinal lymph nodes are the first and most common site of regional spread. However, for the specific patient group defined in this scenario (FIGO Stage IA), the risk of lymph node metastasis is exceptionally low, consistently reported to be less than 1%. This low pre-test probability is the fundamental reason that routine imaging is not recommended.

Pelvic Lymph Node Metastasis: Spread to the pelvic lymph nodes is a secondary event that almost never occurs without prior involvement of the inguinal nodes. In a patient with clinically negative inguinal nodes and a Stage IA primary tumor, the risk of pelvic node involvement is virtually zero.

Distant Metastatic Disease: The possibility of cancer spreading to distant sites like the lungs, liver, or bone is exceedingly rare in the context of such an early-stage primary tumor. Workup for distant disease is not warranted unless there are specific signs or symptoms suggesting its presence.

The clinical workup, therefore, is not focused on finding disease with imaging, but rather on confirming the very low-risk status of the patient through meticulous clinical and pathological assessment.

Why Is Cross-Sectional Imaging ‘Usually Not Appropriate’ for This Presentation?

For patients with a primary vulvar tumor ≤2 cm and ≤1 mm of stromal invasion, the ACR rates all cross-sectional and functional imaging modalities as Usually not appropriate. This includes CT, MRI, and FDG-PET/CT. The rationale is grounded in balancing the near-zero clinical yield against the potential for harm from false-positive results and unnecessary radiation exposure.

The primary reason to avoid imaging is the low pre-test probability of nodal disease. The likelihood of a patient in this category having a positive lymph node is less than 1%. No current imaging modality has perfect specificity. Therefore, in a low-prevalence population, a positive finding on a scan is more likely to be a false positive (e.g., a reactive or inflammatory node) than a true metastasis. This can trigger a cascade of unnecessary anxiety, further testing, and potentially morbid procedures like a full inguinal lymphadenectomy, which carries a high risk of chronic lymphedema.

Why Alternatives Also Receive a Low Rating:

  • FDG-PET/CT (Radiation Level: ☢☢☢☢ 10-30 mSv): While highly sensitive for metastatic disease in many cancers, PET/CT lacks the spatial resolution to reliably detect the microscopic nodal deposits that would represent the earliest form of spread. Furthermore, its specificity is limited, as inflammatory and reactive nodes are common in the groin and can be FDG-avid, leading to a high rate of false positives in this context.
  • CT and MRI of the Pelvis (Radiation Level for CT: ☢☢☢ 1-10 mSv): These modalities rely on size criteria and morphologic features (like necrosis or rounded shape) to identify suspicious lymph nodes. They cannot detect cancer in normal-sized nodes (micrometastases) and have poor overall accuracy for staging clinically negative groins. The added radiation from CT is not justified given the low diagnostic yield.

The clinical consensus, reflected in the ACR guidelines, is that the potential harms of imaging—false positives, radiation exposure, and downstream procedural complications—far outweigh the negligible chance of detecting occult disease in this specific, low-risk patient population.

What Is the Correct Downstream Workflow Without Pre-Treatment Imaging?

If pre-treatment imaging is not performed, the staging and management pathway relies on a meticulous clinical exam and definitive surgical pathology. The workflow is primarily surgical.

  • Positive Finding (Clinically Suspicious Node): If, during the initial or pre-operative physical examination, an inguinal lymph node becomes palpable or suspicious, the patient no longer fits this scenario. The immediate next step is an ultrasound of the groin. If the ultrasound confirms a suspicious-appearing node, an ultrasound-guided fine-needle aspiration (FNA) or core biopsy is performed. A positive biopsy confirms nodal metastasis and upstages the patient, necessitating a completely different treatment plan that may include neoadjuvant therapy or a radical lymphadenectomy.
  • Negative Finding (Clinically Negative Groin): For the majority of patients in this scenario, the groins will be clinically negative. The standard treatment is wide local excision of the primary tumor. The role of inguinal lymph node assessment is debated for this specific group. Historically, no nodal surgery was performed. Many current guidelines suggest that for invasion between 0 and 1 mm, a sentinel lymph node biopsy (SLNB) can be considered to pathologically confirm the absence of micrometastatic disease, though this should be a shared decision based on institutional expertise and patient factors.
  • Indeterminate Finding: An equivocal physical exam is a common clinical challenge. If there is uncertainty about the palpability of a node, the most appropriate next step is a diagnostic groin ultrasound to clarify. This serves as a targeted problem-solving tool rather than a routine staging scan.

The final stage is determined by the pathology from the surgical excision and, if performed, the sentinel lymph node biopsy.

Pitfalls to Avoid in Staging Low-Risk Vulvar Cancer

Navigating the staging of very early vulvar cancer requires resisting the urge to order “routine” scans and instead relying on precise clinical and pathological criteria.

  1. Ordering Scans Out of Habit: Avoid ordering a “pan-scan” (CT chest/abdomen/pelvis) simply because “cancer” is in the diagnosis. This is the most common pitfall and leads directly to the risk of false-positive findings and unnecessary radiation.
  2. Confusing Tumor Thickness with Invasion Depth: The critical measurement for this guideline is the depth of stromal invasion, not the overall tumor thickness. Ensure you have identified the correct value from the pathology report, as it is the single most important predictor of nodal metastasis.
  3. Neglecting the Physical Exam: In the absence of imaging, a meticulous, high-quality physical examination of the groins is the most important staging investigation. A cursory exam can miss a subtle but clinically significant node that would change management entirely.

If the physical exam is equivocal or a node feels prominent, do not proceed directly to surgery. The correct escalation is to order a targeted groin ultrasound, potentially with a plan for ultrasound-guided FNA if a suspicious node is confirmed.

Related ACR Topics and Tools

For a comprehensive overview of imaging recommendations across all vulvar cancer presentations, from early-stage to recurrent disease, please consult our parent topic guide. Additional tools are available to help select the right test and understand its technical parameters.

Frequently Asked Questions

What is the actual risk of lymph node metastasis for a patient with a T1a vulvar cancer (≤2 cm and ≤1 mm invasion)?

The risk is exceptionally low. Large studies and meta-analyses consistently place the risk of inguinal lymph node metastasis in this specific patient population at less than 1%. This low pre-test probability is the primary reason why routine staging imaging is not recommended.

If my patient has a 1.5 cm tumor but the pathology shows 2 mm of stromal invasion, does this ‘no imaging’ guidance still apply?

No, it does not. The depth of stromal invasion is a critical factor. A patient with greater than 1 mm of invasion has a significantly higher risk of nodal metastasis and falls into a different clinical scenario. That patient would typically be considered for imaging, such as a pelvic MRI or CT, to evaluate the inguinal nodes.

What should I do if my patient is very anxious and requests a ‘full body scan’ for reassurance?

This is a common situation that requires careful patient counseling. It is important to explain that for her specific low-risk cancer, a scan is much more likely to find a false positive—an incidental finding that leads to more tests, anxiety, and potential harm—than it is to find actual cancer. Reassure her that the standard of care is based on avoiding these harms and that a meticulous physical exam and surgical pathology are the most accurate ways to ensure her cancer is properly staged and treated.

Is sentinel lymph node biopsy (SLNB) considered an imaging procedure?

SLNB is a surgical procedure that uses an imaging agent. It involves injecting a radiotracer and/or a blue dye (lymphoscintigraphy) to map the lymphatic drainage from the tumor to the first ‘sentinel’ node. While it uses a nuclear medicine imaging technique, it is performed as part of surgery to acquire tissue for pathologic analysis. The ACR rates diagnostic lymphoscintigraphy as ‘Usually not appropriate’ as a standalone pre-treatment staging test in this scenario.

My physical exam of the groin is equivocal. I think I might feel a small node, but I’m not sure. What is the next step?

An equivocal exam is the main indication to deviate from the ‘no imaging’ pathway. The appropriate next step is not a full CT or PET scan, but a targeted diagnostic ultrasound of the groins. Ultrasound can characterize the lymph nodes based on size, shape, and internal architecture. If a node appears suspicious on ultrasound, an ultrasound-guided fine-needle aspiration (FNA) can be performed to get a cytologic diagnosis.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 29, 2026